The gold standard — and the gold standard problem
Human growth hormone (HGH) is a 191 amino acid single-chain polypeptide produced by somatotroph cells in the anterior pituitary gland. It is the master anabolic and lipolytic hormone — responsible for growth during childhood, maintenance of body composition throughout life, and regulation of metabolism via IGF-1 production in the liver.
Cadaveric GH was first used to treat a patient in 1958. For 27 years it was extracted from human pituitary glands at autopsy — a supply limited by cadaver availability and contaminated by the prion responsible for Creutzfeldt-Jakob disease (CJD), leading to the deaths of hundreds of patients before the product was withdrawn in 1985. That same year, Genentech received FDA approval for the first recombinant human growth hormone (rhGH) — somatropin — produced from bacteria expressing the human GH gene. This eliminated the CJD risk and dramatically increased supply.
The FDA has approved rhGH for three adult indications: GH deficiency (GHD) due to pituitary tumours or their treatment; HIV-associated muscle wasting; and short bowel syndrome. There are also eight approved paediatric indications. Prescribing rhGH for anti-ageing purposes in healthy adults without documented GHD is explicitly not FDA-approved and is specifically prohibited under US law — the Controlled Substances Act was amended in 1990 to restrict GH prescribing, making it illegal to prescribe GH except for its approved indications.
Despite this, rhGH is one of the most widely used drugs in anti-ageing and functional medicine globally — prescribed off-label through grey-market channels, compounding pharmacies, and in countries with different regulatory frameworks. Its combination of real anabolic and lipolytic effects with a demanding side effect profile and significant legal complexity makes it the most contested entry in this reference.
US Legal Status: Prescribing HGH for anti-ageing, athletic performance, or body composition in the absence of documented GH deficiency is explicitly illegal in the United States under the Anti-Drug Abuse Act of 1988 and the Controlled Substances Act. Physicians who prescribe it for these purposes risk criminal prosecution. This is not a grey area — it is a specific federal prohibition. The situation differs in other countries.
The most powerful anabolic-lipolytic hormone
Mechanism of Action
The landmark Rudman et al. (1990) NEJM study — often cited as the foundation of GH anti-ageing use — gave 6 months of rhGH to healthy men over 65 with low IGF-1. The results showed increased lean body mass, decreased adipose tissue, and improved bone mineral density. This study generated enormous excitement and remains frequently cited despite its significant limitations: 12 men, 6 months, no placebo-controlled long-term data, and significant side effects.
The 2007 Liu et al. meta-analysis (18 controlled trials of rhGH in healthy elderly) concluded that GH produced modest body composition improvements alongside increased adverse events — joint pain, oedema, carpal tunnel syndrome, and insulin resistance — and that evidence was insufficient to recommend GH as an anti-ageing therapy. The key distinction the evidence consistently makes: GH is powerfully effective in patients with confirmed GH deficiency; in endocrinologically normal healthy adults, the benefit-risk ratio is far less favourable.
What people report
"2IU per day for 6 months. Skin quality improved noticeably. Body fat dropped, especially around the abdomen, without changing training or diet. Sleep quality was markedly better. The carpal tunnel in my right hand was an annoyance but went away after I dropped to 1.5IU. Nothing that GH secretagogues couldn't approximate at a fraction of the cost and risk."
Male, 49, anti-ageing clinic patient. The carpal tunnel syndrome (from fluid retention and nerve compression) is the most consistently reported side effect at doses above 2IU. Dose titration is the standard management. The cost point is significant — pharmaceutical rhGH runs $500–2000/month; secretagogues achieve similar outcomes at $50–200/month.
"Used GH at 4IU/day for a bodybuilding competition prep alongside insulin and anabolic steroids. The results were extraordinary. So were the side effects — permanent gut distension, a pre-diabetic HbA1c that took a year to normalise after stopping. The dose matters enormously. What anti-ageing clinics prescribe and what bodybuilders use are completely different protocols."
Male, 38, competitive bodybuilder. This report illustrates the critical dose distinction. Anti-ageing clinic doses (1–3 IU/day) and bodybuilding doses (4–10 IU/day or more) represent entirely different risk profiles. The gut distension ("HGH gut" or "palumboism") at high doses is caused by visceral organ growth from supraphysiological IGF-1.
What the data shows
rhGH vs GH secretagogues
For most people considering GH axis interventions for anti-ageing or body composition, GH secretagogues (sermorelin, CJC-1295, Mod-GRF + ipamorelin) offer a more physiological, lower-risk, and dramatically cheaper alternative to rhGH. They achieve meaningful GH and IGF-1 elevation through the body's own regulatory system, with comparable body composition results in most clinical populations. The case for rhGH over secretagogues is strongest in confirmed GHD patients where pituitary reserve is insufficient to respond to stimulation.
Risks & considerations
⚠ Key Warnings
Nutrients, Supplements & Monitoring
If using rhGH under physician supervision for approved indications, the synergy stack focuses on maximising body composition outcomes while actively managing the principal risks — insulin resistance, fluid retention, and IGF-1 elevation.
Disclaimer: This entry is educational. rhGH for anti-ageing or performance enhancement in healthy adults is illegal in the United States. For body composition and GH axis optimisation, GH secretagogues (sermorelin, CJC-1295, Mod-GRF + ipamorelin) achieve comparable results within a more appropriate legal and safety framework for most non-GHD individuals.
Editor's summary
HGH is simultaneously one of the most powerful and most misunderstood interventions in this book. In patients with confirmed GH deficiency — where the pituitary is genuinely unable to produce adequate GH — rhGH therapy is transformative. The evidence for GHD treatment is strong, the benefits are real, and the regulatory approval is appropriate.
The controversy surrounds its use in healthy adults. The honest evidence: visceral fat reduction is the most reliably demonstrated benefit. Lean mass increases are modest and largely water and connective tissue rather than functional muscle. Skin, sleep, and wellbeing improvements are real but modest. The side effect profile — insulin resistance, fluid retention, carpal tunnel, potential cancer acceleration — is substantial even at therapeutic doses and escalates dramatically at performance doses.
For most people pursuing GH axis optimisation outside of documented GHD, the calculus favours secretagogues over exogenous GH. Secretagogues produce physiologically regulated GH elevation at a fraction of the cost, with a more favourable safety profile, without suppressing endogenous pituitary function, and without the US legal prohibition on anti-ageing use. They are not as powerful — nothing produces the effects of direct GH replacement at performance doses — but for most legitimate health and anti-ageing goals, they are the better tool.
The bodybuilding use at supraphysiological doses — which is what most public discourse about "GH" refers to — is an entirely different conversation. The visceral organ growth, permanent acromegalic features, and metabolic consequences at those doses are not extensions of the therapeutic risk profile. They are a categorically different risk category, and this distinction is consistently lost in community discussions.